Suitcase Lab for Rapid Detection of SARS-CoV-2 Based on Recombinase Polymerase Amplification Assay
Authors
Affiliations
In March 2020, the SARS-CoV-2 virus outbreak was declared as a world pandemic by the World Health Organization (WHO). The only measures for controlling the outbreak are testing and isolation of infected cases. Molecular real-time polymerase chain reaction (PCR) assays are very sensitive but require highly equipped laboratories and well-trained personnel. In this study, a rapid point-of-need detection method was developed to detect the RNA-dependent RNA polymerase (RdRP), envelope protein (E), and nucleocapsid protein (N) genes of SARS-CoV-2 based on the reverse transcription recombinase polymerase amplification (RT-RPA) assay. RdRP, E, and N RT-RPA assays required approximately 15 min to amplify 2, 15, and 15 RNA molecules of molecular standard/reaction, respectively. RdRP and E RT-RPA assays detected SARS-CoV-1 and 2 genomic RNA, whereas the N RT-RPA assay identified only SARS-CoV-2 RNA. All established assays did not cross-react with nucleic acids of other respiratory pathogens. The RT-RPA assay's clinical sensitivity and specificity in comparison to real-time RT-PCR ( = 36) were 94 and 100% for RdRP; 65 and 77% for E; and 83 and 94% for the N RT-RPA assay. The assays were deployed to the field, where the RdRP RT-RPA assays confirmed to produce the most accurate results in three different laboratories in Africa ( = 89). The RPA assays were run in a mobile suitcase laboratory to facilitate the deployment at point of need. The assays can contribute to speed up the control measures as well as assist in the detection of COVID-19 cases in low-resource settings.
Developing, Characterizing, and Modeling CRISPR-Based Point-of-Use Pathogen Diagnostics.
Jung J, Dreyer K, Dray K, Muldoon J, George J, Shirman S ACS Synth Biol. 2024; 14(1):129-147.
PMID: 39670656 PMC: 11744932. DOI: 10.1021/acssynbio.4c00469.
Song Y, Fang Y, Zhu S, Wang W, Wang L, Chen W Front Cell Infect Microbiol. 2024; 14:1474676.
PMID: 39507945 PMC: 11538013. DOI: 10.3389/fcimb.2024.1474676.
Sun S, Zhao Y, Hao Y, Xue P, Guo X, Zhang W Biomed Opt Express. 2024; 15(9):5215-5226.
PMID: 39296394 PMC: 11407254. DOI: 10.1364/BOE.535051.
Developing, characterizing and modeling CRISPR-based point-of-use pathogen diagnostics.
Jung J, Dreyer K, Dray K, Muldoon J, George J, Shirman S bioRxiv. 2024; .
PMID: 39005318 PMC: 11244977. DOI: 10.1101/2024.07.03.601853.
Hanifehpour H, Ashrafi F, Siasi E, Fallahi S BMC Infect Dis. 2024; 24(1):679.
PMID: 38982392 PMC: 11232332. DOI: 10.1186/s12879-024-09574-9.